Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
immatics biotechnologies GmbH is a business based in the US. immatics biotechnologies GmbH shares (IMTXW) are listed on the NASDAQ and all prices are listed in US Dollars. immatics biotechnologies GmbH employs 134 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.04 |
|---|---|
| 52-week range | $0.88 - $5.55 |
| 50-day moving average | $0.00 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | N/A |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.04 from 2022-06-30
| 1 week (2022-06-27) | 2.00% |
|---|---|
| 1 month (2022-06-03) | 21.43% |
| 3 months (2022-04-05) | -5.12% |
| 6 months (2022-01-05) | -47.56% |
| 1 year (2021-07-01) | -40.00% |
|---|---|
| 2 years (2020-07-02) | -62.91% |
| 3 years (2019-07-01) | N/A |
| 5 years (2017-07-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | -156.4% |
| Book value | N/A |
| Market capitalisation | $673 million |
TTM: trailing 12 months
We're not expecting immatics biotechnologies GmbH to pay a dividend over the next 12 months.
Immatics N. V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors through two distinct therapeutic modalities, such as Adoptive Cell Therapies and antibody-like TCR Bispecifics. Its pipeline comprises of eight therapeutic programs, of which four are in clinical trials and four are in preclinical development. The company is based in Tuebingen, Germany. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.